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Summary 
CD2, a cell surface glycoprotein expressed on T cells and natural killer cells, can couple to sig- 
naling pathways that result in T cell proliferation. An Src-like protein tyrosine kinase, p50 ok, 
coprecipitates with CD2, and perturbation of CD2 by monoclonal antibodies results in an in- 
crease in the activity of p56 kk, suggesting that an interaction with p56 l~k contributes to CD2- 
mediated signaling. Herein, we investigate the mechanism by which CD2 associates with 
p561ok. We demonstrate hat CD2 and p56 l~k associate when coexpressed in nonlymphoid cells, 
that this association requires the cytoplasmic domain of CD2, and that the SH3 domain of 
p561ok mediates its interactions with CD2. Using truncation mutants of CD2, we identify two 
regions in the cytoplasnfic domain of CD2 involved in binding p56 kk. Each region contains a 
proline-rich sequence that, in the form of a synthetic peptide, directly binds p56 lck. Thus, pro- 
line-rich sequences in the cytoplasmic domain of CD2 allow this transmembrane receptor to 
bind to the SH3 domain of p561ok. 
variety of receptor-ligand interactions occur when T 
ymphocytes recognize and respond to antigenic pep- 
tides bound to MHC molecules on the surfaces of other 
cells. Although this response depends on the TCR,  other 
cell surface molecules contribute to T cell activation by 
promoting adhesion to the APC and by providing bio- 
chemical signals. CD2, a 55-kD cell surface glycoprotein 
expressed by T lymphocytes and NK cells, subserves adhe- 
sion functions by binding CD48, CD58, and CD59 (1-3). 
It is likely that CD2 also has a role in generating transmem- 
brahe signals during the activation of T cells and NK cells 
(4, 5). Perturbation of CD2 can trigger the cytolytic activ- 
ity of NK cells and can provide a potent stimulus for T cell 
activation, inducing proliferative responses comparable to 
those elicited by either mitogenic lectins or mAbs to the 
TC1K (4, 5). In several experimental systems, CD2-medi- 
ated signaling augments antigen-induced activation of T 
cells (6, 7). Moreover, administration ofnondepleting CD2 
mAbs to mice induces T cell unresponsiveness, indicating 
that CD2 either has a critical role in T cell activation in 
vivo or can deliver signals leading to unresponsiveness (8). 
CD2-deficient mice, however, do not manifest an obvious 
phenotype, suggesting that, i fCD2 does have a critical role 
in physiological T cell activation, other molecules can as- 
sume that role when T lymphocytes develop in the absence 
of CD2 (9). Alternatively, the functional deficit resulting 
from the abscence of CD2 may be subtle. Of  interest in this 
regard, recent data suggest that CD2 plays a unique role in 
the reversal o fT  cell anergy in vitro (10). 
The mechanism by which CD2 couples to signal trans- 
duction pathways i uncertain. When T cells are lysed with 
digitonin or Brij, CD2 coimmunoprecipitates with the 
TCR (11-14). Therefore, like CD4 and CD8, CD2 ap- 
pears to be in close physical proximity with the TCR (11- 
14). Indeed, CD2-mediated activation requires coexpres- 
sion of TCR or of receptor complexes, uch as CD16, that 
contain the TCk-{  chain or the closely related Fce recep- 
tor ~ chain (15, 16). Thus, agonist mAbs to CD2 fail to ac- 
tivate T cell lines that express abundant CD2 but that lack 
TCR (15). As is the case with the TCP.., appropriate stim- 
ulation of CD2 induces tyrosine phosphorylations and 
polyphosphoinositide turnover (17-20). These CD2-induced 
signaling events depend on the cytoplasmic domain of CD2, 
which is relatively large (116 amino acids), is highly con- 
served between human, rat, and mouse, and lacks intrinsic 
kinase activity (21-24). 
The remarkable capacity of CD2 to activate T ceils and 
NK cells raises the possibility that, like the TCR,  CD4, and 
CD8, CD2 interacts with cytoplasmic protein tyrosine ki- 
nases (PTK). 1 Several observations support his possibility. 
Perturbation of CD2 induces protein tyrosine phosphoryla- 
1Abbreviations u ed in this paper: F.L., full-length; GST, glutathione-S-trans- 
ferase; PTK, protein tyrosine kinases; S/9, Spodopterafrugiperda. 
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tions, and CD2 signaling requires expression of CD45, a 
transmembrane tyrosine phosphatase that regulates the ac- 
tivities of Src-like PTK (20, 25). Stimulation of CD2 on T 
cells leads to an increase in the specific activity of p56 kk, a 
lymphoid-specific Src-like PTK (26). We and others have 
found that p561Ck as well as p59 fin coimmunoprecipitate 
with CD2 from detergent lysates of rat T lymphocytes and 
NK cells, raising the possibility that CD2 associates directly 
with these Src-like PTK (12, 13, 27). Herein we examine 
the mechanism by which CD2 associates with p56 kk. 
Materials and Methods 
Cell Lines, Cell Culture, mAbs, and Other Reagents. COS 6M 
cells were grown in DME with 10% FCS. Spodopterafrugiperda 
(sfg) cells were grown in complete Grace's medium. Anti-rat 
CD2 mAbs OX-34, OX-54, and OX-55 were the kind gift of A. 
Williams (Oxford University, Oxford, UK). 
Generation of Fusion Proteins and Anti-GST Antiserum. The don- 
ing of Wild Type p56 kk into the baculovims shuttle vector pBMS-1 
has been previously reported (28). Domains encompassing the 
unique regions SH2 and SH3 were cloned in frame with GST 
into the pGEX-2T vector (Pharmacia, Uppsala, Sweden) by PCR. 
The unique sequence fusion encompassed amino acids 8-65, 
whereas the SH3 and SH2 fusions encompassed amino acids 66-113 
and 114-235, respectively, of the Wild Type gene. The unique 
sequence and GST alone were produced with isopropyl-[3-D- 
thiogalactopyranoside according to the manufacturer's instruc- 
tions (Pharmacia LKB Biotechnology Inc., Piscataway, NJ) and 
used for injections in New Zealand white rabbits for polyclonal 
antisera production. HIS-T7 epitope-tagged fusion proteins were 
made by cloning the appropriate portions of the rat CD2 cyto- 
plasmic domain in frame into the pet-28 vector (Novagen, Inc., 
Madison, WI) by PCR. Protein production was induced with 
IPTG and purified according to the manufacturer's in tructions. 
Generation ofCD2Mutants. The CD2 truncation mutants 
were generated by PCP- using the rat cDNA provided by A. 
Williams. The 5' oligonucleotide located upstream of the CD2 
start site contained an EcoRI site and was used for all PCR. Its se- 
quence is5'-TATATATATAGAATTCCACTGGGA AAGAA- 
TGTAAAGATGAGATG-3'. To generate the truncation mutants, 
we synthesized antisense oligonucleotides containing a stop 
codon after the appropriate amino acid followed by restriction 
sites. The sequences for CY6, CY40, CY78, CY85, and CY105 
are 5'-TATTTAAGCTTGCGGCCGCTAGTTCCGTTTTTT- 
CCTCTTCA-3', 5'-TATATATATGAATTCGTCGACCTA- 
TGATGCTGGTGAGGCCTGGGTTGAGTGTGGCTTGGG- 
3', 5'-TATATAATAGTCGACGCGGCCGCCTATCTCTTC- 
TTCGGCTGGTGCTCACG-3', 5'-TATAATATAGTCGAC- 
GCGGCCGCTACTGTGTGCCTGATGGAGGAGGTCTC-3', 
and 5'-TATATATATGAATTCGTCGACCTAACAGGGAGG- 
CTTTGGCTGAACTCGGGGTCTGGGCAAAGG-3', respec- 
tively. The PCR products were cloned into pSM for expression 
in COS cells and pVL1393 for recombination with BaculoGold 
DNA and expression in Sf9 cells (PharMingen, San Diego, CA). 
The internal deletion designated CY49.69 (lacking amino acids 
49-69 of the cytoplasmic tail of rat CD2) was generated by over- 
lap PCR as described (29). 5' and 3' overlapping PCR fragments 
were generated for the internal deletion. Oligonuceotides u ed 
for the PCR reactions were as follows: 5' fragment of CY49.69, 
5'-TATATATATAGAATTCCACTGGGAAAAGAATGTAAA- 
GATGAGATG-3' and 5'-CTTCGGCTGGTGCTCACGGTT- 
AGCTTGGGAAGCCACTGGATT-3'; and the 3' fragment of 
CY49.69, 5'-AATCCAGTGGCTTCCCAAGCTAACCGTGAG- 
CACCAGCCGAAG-3' and 5'-TATAAAGTCGACGCGGCC- 
GCTTAATTAGGGGGTGGCAACGAAAC-3'. The internal 
deletion designated CY7.4l (lacking amino acids 7-41 of the cyto- 
plasmic tail of rat CD2) was also generated by overlap PCR using 
the following primers: 5' fragment of CY7.41, 5'-TATATAGAA- 
TTCCACTGGGAAAAGAATGTAAAGATGAGATG-3' and 5'- 
GTGCTCACGGTTGCCAGGTGTCTGGAGATG-3'; and the 
3' fragment of CY7.4l, 5'-CAGACACCTGGCAACCGTGAG- 
CACCAGCCG-3' and 5'-TATAAAGTCGACGCGGCCGCT- 
TAATTAGGGGGTGGCAACGAAAC-3'. The DNA sequence 
of the cytoplasmic domain of each mutant was verified. 
Expression of Full-Length and Mutant CD2 and p5~ "k in COS 
Cells and Sf9 Cells. The various CD2 constructs and p56 lck were 
expressed inCOS cells by transient transfection using DEAE dex- 
tran (Sigma Chemical Co., St. Louis, MO) according to pub- 
lished methods (30). To express the constructs in Sf9 cells, we 
transfected the various constructs into Sf9 cells in the presence of 
BaculoGold DNA (PharMingen) according to the manufacturer's 
instructions, harvested, and amplified the recombinant baculovi- 
rus. The virus was then used for large-scale preparations of re- 
combinant protein. 
Immunoprecipitations, I  Vitro Kinase Assays, and Immunoblot- 
ring. Anti-CD2 immunoprecipitations were performed using 
either mAb OX-34 (mouse IgG2b) coupled to Pansorbin cells 
(Calbiochem Corp., LaJolla, CA), or mAb OX-55 (mouse IgG1) 
coupled either to Pansorbin cells coated with rabbit anti-mouse 
Ig antiserum (Cappel Laboratories, Malverne, PA) or to Sepha- 
rose-coupled goat anti-mouse Ig (Cappel Laboratories). In vitro 
kinase assays were performed as described (27). Anti-GST immu- 
noblots were performed by blocking the gel transferred to Immo- 
bilon-P (Millipore Corp., Bedford, MA) in 20 mM Tris, pH 8, 
150 mM NaC1, 0.05% Tween 20 (TBST) with 3% nonfat dried 
milk for 30 min followed by incubation with anti-GST antiserum 
(1:500 in TBST with 3% milk) for 2 h at room temperature. The 
blots were washed three times for 5 rain in TBST and incubated 
with 12SI-labeled protein A (Amersham Corp., Arlington Heights, 
IL) at 0.5 mCi/rnl in TBST with 3% milk for 1 h at room tem- 
perature. The blots were washed three times for 5 rain in TBST, 
dried, and evaluated by autoradiography. Anti-rat CD2 immuno- 
blots were performed as above using mAb OX-34 at 0.1 Izg/ml 
in TBST with 3% milk, and anti-T7 immunoblots were per- 
formed using anti-T7 mAb (Novagen, Inc.) according to the 
manufacturer's in tructions. 
Peptide Generation. The peptides used in these studies were 
purchased from either Chiron Mimotopes Peptide Systems (San 
Diego, CA) or Research Genetics (Huntsville, AL), analyzed by 
mass pectometery or HPLC, and were I>70% pure. The sequences 
of each peptide are as follows: peptide 1, ASQAPPPPGHH; pep- 
tide 2, PGHRPLPPSHR; peptide 3, PKKRPPPSGTQ; peptide 
4, GQKGPPLPIq.PRV; and peptide 5, RVQPKPPCGSG. (Pep- 
tide 4 is a 12-met; a glycine was added to the NH 2 terminus to 
prevent cyclization of the NH2-terminal glutamine.) Equivalent 
molar quantities of the peptides were conjugated toactivated CH 
Sepharose 4B (Pharmacia LKB Biotechnology Inc.) per the man- 
ufacturer's instructions and were used to precipitate purified 
GST/p561ok. 
Determination f Ca 2§ Fluorescence and IL-2 Production. Jurkat 
cells were loaded with the Ca2+-sensitive fluor and lndo-1, and 
calcium fluorescence was monitored as previously described (31). 
To determine IL-2 production, we cultured Jurkat cells at 1() ~ 
cells/ml in 96-well plates and stimulated the cells for 18 h with 
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Figure 1. Protein kinase activity 
coprecipitates with CD2 from rat T 
cells. Freshly isolated rat splenic T cells 
were lysed in a buffer containing 1% 
NP-40, and 500 lig of the precleared 
lysate was subjected to immunopre- 
cipitation with antibodies directed 
against either CD2 (OX-34), CD4 
(W3-25), or CD8 (OX-8) as indi- 
cated. The immune complexes were 
washed and incubated in akinase reac- 
tion buffer containing 10 p, Ci of 
[~/-32p]ATP as previously described 
(27). Phosphoproteins were separated 
by SDS-PAGE on an 8% gel, treated 
with 1 M KOH at 55~ for 1 h, and 
evaluated by autoradiography. Molec- 
ular masses and the location of p56 kk 
are indicated on the left. 
media, PMA alone (10 ng/ml), the combination of OX-54 (20 
I~g/ml), OX-55 (20 Ixg/ml) and PMA, or the combination of 
C305 (1:500 dilution from ascites) and PMA. Culture supema- 
tants were assayed for IL-2 using a human IL-2 cytoscreen immu- 
noassay kit (Biosource International, Camarillo, CA) according to 
the manufacturer's in tructions. 
Results 
CD2 and p561ok Associate in Rat T Cells, and This Associa- 
tion Can Be Reproduced in COS Cells. As is the case with 
CD4 and CD8, immunoprecipitates of CD2 from 1% 
NP-40 lysates of splenic T cells contain aprotein kinase ac- 
tivity detected by in vitro kinase assays (Fig. 1). We and 
others have identified p56 kk as one of the PTKs present in 
these CD2 immunoprecipitates (12, 13, 27). To determine 
whether CD2 and p56 lck can associate in a nonlymphoid 
cell line, we transfected COS cells (a fibroblast line that 
does not express p56 kk) with cDNAs encoding p56 lck and 
rat CD2. After 72 h, the cells were solubilized in a buffer 
containing 1% NP-40, and the resulting lysate was sub- 
jected to immunoprecipitation with antibodies directed 
against CD2 and p56 kk (Fig. 2 A). An in vitro kinase assay 
performed on the CD2 immunoprecipitate g nerated 
prominent phosphorylated bands that comigrated with au- 
tophosphorylated p56 lck. The presence of kinase activity in 
the CD2 immunoprecipitate r quired transfection with 
both the CD2 and p56 lck cDNAs. There was no kinase ac- 
tivity in CD2 immunoprecipitates from COS cells trans- 
fected with p56 lck alone, indicating that the CD2 mAb does 
not cross-react with a PTK. Similarly, in vitro kinase reac- 
tions on CD2 immunoprecipitates from COS cells trans- 
fected with CD2 alone failed to reveal bands corresponding 
to Src-family members. Taken together, these results indi- 
cate that rat CD2 and p56 Ick associate when coexpressed in
COS cells. Comparable results were obtained when human 
CD2 was coexpressed with p56 lck in COS ceils (data not 
shown). CD2, therefore, does not require the expression of 
any other lymphoid specific molecules to associate with p56 lck. 
CD2 also binds p56 kk when the latter is in the form of a 
purified GST fusion protein. After incubating GST/p56 kk 
with lysate from CD2-expressing COS cells, we immuno-  
precipitated CD2 and then analyzed the immunoprecipi- 
tate for the presence of GST/p56 lck by immunoblott ing 
with an antiserum to GST. As shown in Fig. 2 B, GST/  
p56 l~k coprecipitates with CD2. This association requires 
the presence of the CD2 cytoplasmic domain, as evidenced 
by the failure to detect GST/p56 kk in immunoprecipitates 
of a truncation mutant o fCD2 (CY6) that lacks all but the 
first six amino acids of the cytoplasmic domain of CD2. 
The SH3 Domain of p56 l"k Mediates Association with CD2. 
To determine the region of p561ok that binds to CD2, we 
constructed GST fusion proteins containing the following 
domains of p56kk: the NH2-terminal unique region, the 
SH3 domain, and the SH2 domain (Fig. 3). In these exper- 
iments, we used Sf9 cells (a blowfly salivary gland cell line) 
that expressed CD2 after gene transfer. Each of the fusion 
proteins was incubated with equal aliquots of CD2- 
expressing Sf9 lysate, and then immunoprecipitations with 
anti-CD2 mAb were performed. The immunoprecipitate 
was analyzed by inmmnoblott ing with anti-GST. The 
GST/SH3 domain fusion protein coprecipitated with CD2, 
but GST alone, the GST/unique region fusion protein, and 
the GST/SH2 domain fusion protein did not (Fig. 4 A). 
Next we determined if the GST/SH3 domain fusion pro- 
tein could competitively inhibit the association of CD2 
with full-length GST/p56 kk (we used the fusion protein 
rather than p56 Ick because the fusion protein could be easily 
purified, permitting better control of its concentration). In 
each of several experiments, the GST/SH3 domain fusion 
protein, but not GST/unique region or GST alone (data 
not shown), inhibited the binding of CD2 to GST/p561ok 
(Fig. 4 B). As was the case with GST/p56 lck, the GST/SH3 
domain fusion protein associated with full-length (F.L.) 
Figure 2. The association f CD2 with p56 kk can be re- 
produced in nonlymphoid cells and requires the cytoplasmic 
domain of CD2. (A) p56 lck coprecipitates with rat CD2 
when expressed in COS ceils. COS cells were plated onto 
100-cm 2 dishes and transfected with 5 ~g of plasrmd DNA 
encoding the molecules indicated (Tx). After 72 h, the cells 
were lysed in buffers containing 1% NP-40, and the pre- 
cleared lysates were subjected o immunoprecipitation with 
the indicated antibodies (IP). The immune complexes were washed and incubated in a kinase reaction buffer containing 20 p.Ci of ['y-32p]ATP. hos- 
phoproteins were separated bySDS-PAGE on an 8% gel and evaluated byautoradiography. OX-55 (anti-rat CD2 mAb), OX-8 (isotype-matched con- 
trol mAb recognizing rat CD8), and crick (rabbit antiserum recognizing p56 kk) were used inthe immunoprecipitations. (B) GST/p56 lck fusion protein as- 
sociates with full-length CD2 (F.L.) but not a t illess CD2 construct (CY6) produced inCOS cells. 3 p,g of purified GST/p56 I~k was added to a COS cell 
lysate containing either F.L. CD2 or a truncation mutant lacking a cytoplasmic domain (CY6). CD2 was immunoprecipated from the lysates, and the 
CD2 immunoprecipitates were then analyzed by irrmmnoblotting with anti-GST antiserum. 
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CD2 but not the tailless CY6 mutant of  CD2 (Fig. 4 C). 
Similarly, immobil ized GST/SH3 domain fusion protein pre- 
cipitated F.L. CD2, but not CY6, from SJ9 lysates (Fig. 4 D). 
The Cytoplasmic Domain of CD2 Directly Associates with 
p56 tck. To determine if p56 lck binds directly to the cyto- 
plasmic domain of  CD2, we constructed two nickel histi- 
dine T7 epitope-tagged fusion proteins: one of  the full- 
length cytoplasmic domain o fCD2 (T7-CY) and one con-  
taining the first 40 amino acids of  the cytoplasmic domain 
of CD2 (T7-40). The fusion proteins were purified to ho-  
mogeneity, immobi l ized onto Sepharose with an ant i -T7 
mAb, and used to affinity precipitate purified GST/SH3 
fusion protein. The GST/SH3 fusion coprecipitated with 
the full- length cytoplasmic domain but not with the fusion 
protein containing the first 40 amino acids (Fig. 5 A). Sim- 
ilarly, immobi l ized GST/p56 kk fusion protein precipitated 
T7-CY ,  but not T7-40 (Fig. 5 B). These studies indicate 
p56 lck binds directly to the cytoplasmic domain of  rat CD2 
and that the first 40 amino acids of  the cytoplasmic domain 
of  CD2 are not sufficient for this binding. 
Identification of the Minimal Cytoplasmic Domain of CD2 
Required for Binding top56 Ick. To determine the minimal  
Figure 3. Schematic representation of 
p56 l& and the GST/p56 kk fusion proteins. 
The structure of p56 lck can be divided into 
an NHg-terminal myristylation s te (MYR), 
a unique region, SH3 and SH2 domains, a 
catalytic domain, and a COOH-terminal 
regulatory region (REG). 
cytoplasmic domain of  CD2 needed for b inding to p56 kk, 
we constructed a series of CD2 truncations in addition to 
CY6. Mutants containing 40, 78, 85, and 105 of  the 116 
amino acids in the cytoplasmic tail of  rat CD2 were gener- 
ated by PCI< and were designated CY40, CY78, CY85, 
and CY105, respectively (Fig. 6). 
We expressed F.L. CD2 and each of  the mutants in Sf9 
cells and then determined their ability to associate with 
p56 lck. Lysates from the CD2-expressing Sf9 cells were 
combined either with wild-type p56 lck produced in Sf9 
cells (Fig. 7 A) or with purified GST/p561ok (Fig. 7 B). F.L. 
CD2 and the CD2 mutants were immunoprecipitated, and 
the immunoprecipitates were analyzed either by in vitro 
kinase reaction (Fig. 7 A) or by immunoblot t ing  with anti- 
GST antiserum (Fig. 7/3). In both experiments, equivalent 
activities or amounts of  p561ok coprecipitated with F.L. and 
CY105 (Fig. 7). As the cytoplasmic tail of  CD2 was short- 
ened from 105 amino acids to 85 amino acids, there was a 
decrease in the associated p56 lck to r176 of  that seen with 
F.L. (determined by densitometry of  Fig. 7 /3). There was 
no change in the associated p56 lck as the cytoplasmic tail 
was shortened from 85 to 78 amino acids (Fig. 7 B). As the 
Figure 4. The association between CD2 and p56 lck requires the cytoplasmic domain of CD2 and the SH3 domain of p56 kk. (a) After the addition f 
1.5 Ixg of GST, GST/p56 lck unique region, GST/p56 lck SH2 domain, or GST/p56 lCk SH3 domain to S f9 lysate containing F.L. CD2, CD2 was immuno- 
precipitated, and the immunoprecipitate was analyzed for associated fusion protein by anti-GST immunoblotting. (b) 5 Ixg of GST/p56 kk unique region 
or GST/p56 lck SH3 domain (final concentration ~333 nM each) was incubated in 500 txl Sf9 lysate containing F.L. CD2 for 30 rain before the addition 
of 3 btg GST/p56 Ick (66 nM) The lysates were precleared nd then immunoprecipitated with mAb directed against rat CD2 and analyzed for associated 
fusion protein by inmmnoblotting with anti-GST. Binding of the GST/p561ck fusion protein (31 kD) to CD2 is not detected because of its lower mo- 
lecular mass. (c)1.5 txg of GST/p56 kk SH3 domain was added to Sf9 lysate containing either F.L. CD2 or CY6, which was then immunoprecipitated 
with mAb directed against rat CD2 and analyzed for associated fusion protein by immunoblotting. (d) To equimolar amounts of F.L. CD2 and CY6, 
sepharose bound GST/p56 kk SH3 was added and incubated for 1.5 h. The affinity precipitations were separated by SDS-PAGE and immunoblotted with 
anti-rat CD2 mAb. Molecular masses are indicated on the left. Each figure is r presentative of at least three independent experiments. 
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Figure 5. The cytoplasmic tail of CD2 binds directly top56 kk. (a) T7- 
CY (lane 1) and T7-40 (lane 2) purified fusion proteins were immobilized 
onto anti-T7 mAb coupled to Sepharose bound rabbit anti-mouse antise- 
rum and used to affinity precipitate 0.5 Ixg of GST/SH3 fusion protein in 
1% NP-40 lysis buffer. The precipitates were washed three times in lysis 
buffer, eluted with Laemmli sample buffer, separated by SDS-PAGE, and 
immunoblotted with anti-GST antiserum. The presence of equimolar 
amounts of T7-CY and T7-40 was confirmed by immunoblotting with 
anti-T7 mAb (data not shown). (b) To equimolar amounts of T7-CY and 
T7-40 fusion protein, Sepharose b und GST/p56 kk SH3 was added and 
incubated for 1.5 h. The GST fusion protein was eluted in 10 mM glu- 
tathione, and the affinity precipitations were separated by SDS-PAGE and 
immunoblotted with anti-T7 mAb. Molecular masses are indicated on the 
left. Each figure is representative of at least three independent experiments. 
Figure 7. Association of p56 lck with F.L. rat CD2 and truncation and 
internal deletion mutants of rat CD2. Lysates of Sf9 cells expressing F.L. 
or the indicated CD2 mutants were mixed with either p56 ]~k produced in 
Sf9 cells (a) or purified GST/p56 kk fusion protein (b and c). The lysates 
were precleared, immunoprecipitated with anti-rat CD2, and subjected 
to in vitro kinase reactions (a) or immunoblotted with anti-GST antise- 
mm (b and c). Expression of the CD2 constructs was analyzed by flow cy- 
tometry, and anti-CD2 blotting of the lower half of the immunoblots 
confirmed the presence of equimohr concentrations of each of the con- 
structs (data not shown). 
cytoplasmic domain was truncated to 40 amino acids, vir- 
tuaUy all p561Ck b inding was el iminated (Fig. 7). A l though a 
small amount  of  GST/p56  kk was seen in the CY40 immu-  
noprecipitate, this was not  a consistent f inding in other ex- 
periments. Immunoblots  o f  these samples with a mAb to 
extracellular CD2 revealed that there was severalfold more 
CY40 than F.L. (data not shown). When corrected for the 
amount  of  CD2 in the immunoprecipitates in Fig. 7, the 
GST/p56 kk in CY40 immunoprecipitates represents '-~ 
of  that in F.L. CD2 immunoprecipitates. 
The data in Fig. 7 are consistent with two possibilities. 
First, there may be two b inding sites for p56 kk in CD2:  one 
between amino acids 40 and 78 and another between 
amino acids 85 and 105. Alternatively, there may be a 
proximal b ind ing site that is secondarily affected by the 
truncation such that its ability to b ind is impaired. To dis- 
tinguish between these possibilities, we generated two in-  
ternal deletion mutants of  CD2: one lacking amino acids 
49-69 and the other lacking amino acids 7-41 of  the cyto- 
plasmic domain (designated CY49.69 and CY7.41, respec- 
tively; Fig. 6). We expressed F.L. CD2 and each of  the in-  
ternal deletion mutants in SJ9 cells and determined their 
ability to associate with purified GST/p56 kk. Immunopre -  
cipitates of  F.L. CD2 and the CD2 mutants were analyzed 
by immunoblot t ing  with ant i -GST antiserum (Fig. 7 C). In 
each of  several experiments, CY7.41 consistently bound 
more GST/p56 lck than F.L. indicating that the membrane-  
proximal port ion of  the cytoplasmic domain of  CD2 is not  
required for b ind ing to p56 kk. CY49.69 bound GST/  
p56 kk, but  not as well as F.L., CD2,  consistent with a possi- 
ble p56 Ick b inding site between amino acids 40 and 78. 
Taken together with the truncation studies, these data indi-  
cate that CD2 has two discrete regions that b ind p56kk: one 
between amino acids 40 and 78 and the other between 
amino acids 85 and 105 of  the cytoplasmic tail o f  rat CD2.  
Proline-rich Sequences fiom the Cytoplasmk Domain of CD2 
Bind p56 tck. Studies by several investigators indicate that 
the b ind ing sites for SH3 domains are rich in proline resi- 
dues (32-35). The cytoplasmic tail of  CD2 has several pro-  
l ine-r ich domains. Two of  these (amino acids 92-95 and 
F.L 
CYIOS 
CY~ 
CY78 
CY40 
CY6 
CY49.69 
CY7.41 
Figure 6. 
AMINO ACID SEQUENCE OF THE CYTOPLASMIC DOMAIN OF F.L. CD2 AND EACH OF THE CD2 MUTATIONS 
KRKIGRNRRRKOb2h7 ~KA~STVERGPKPB~TQA,~,PASQNPVASQA~I~HI - I LQT IE~IRNREHQ~Q~K~VO~DV$~N 
KRK]C.RNRRRKGI~/~I n IKASRMSTVI~STQASAPASQNPVASQAPPPPGHI~HRPLP~QpKK]p . .pPPSGTQ~KG~RVQ~ 
KRKKRNRRRKGg'b-'T b-'mC, A~STVERGPKIR-ISTQASAPASQNIWASQAPPPPGHHI.QTI~HRPLppsiRRNRI~QPKKRPP~ 
KRKKRNRRRKG~-'T ~CA.SRMSTVI~GPKPHSTQASAPASQNI~VASQAPPPPGHHI~TPGHRPLP~QPKKR 
KRKKRNRRRKGb-'I~ I IKASRMSTV][~GPKPHSTQASAPAS 
KRKKR.,N'RRRKG~ ~'T ~IKASRM STVERGPKPHSTQA SAPASQNPVASQA ~QPKKRPPPSGTQVHQQKGPPLPRPRVQPKPPC~SGDVSLPPPN 
KRKKRN NPVASQAPPPPGHHLQTPG~SHRNREHQPKKRPPPSGTQVHQQKGPPLPRPRVQPKPPCGSGDVS~PpN 
Amino acid sequence of the cytoplasmic domain of F.L. rat CD2 and the various CD2 mutants. Proline-rich regions are underlined in the F.L. 
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101-104; Fig. 6) lie in the putative binding regions indi- 
cated above between amino acids 85 and 105. Two other 
proline-rich regions lie between amino acids 49 and 66, the 
putative binding region deleted in the CY49.69 mutant. A 
fifth proline-rich sequence (amino acids 79-81) lies in a re- 
gion whose truncation had no detectable ffect on the abil- 
ity of  CD2 to associate with p561ok. 
To investigate the possibility that one or more of  the 
CD2 proline-rich sequences could bind p56 lck, we synthe- 
sized 11-mer peptides corresponding to the five proline 
rich regions between amino acids 49 and 105. The peptides 
were coupled to activated Sepharose and then incubated in 
lysis buffer with full-length GST/p56 kk. Eluates from the 
immobilized peptides were assayed for the presence of  
GST/p56 l& by anti-GST immunoblotting. Two peptides 
(designated 2 and 4) consistently bound GST/p56 kk (Fig. 8 
A). Peptide 2 corresponds to amino acids 59-69 and thus 
lies within the putative binding site between amino acids 
40 and 78. Peptide 4 represents amino acids 89-99 and is 
within the putative binding site between amino acids 85 
and 105. Peptide 1, which also lies within the amino acid 
40-79 site, bound GST/p56 l~k poorly (relative to peptides 
2 and 4) in two experiments (Fig. 8 A) or not at all in eight 
experiments (data not shown). Peptide 3 (which resides be- 
tween amino acids 75 and 85) and peptide 5 (which resides 
between amino acids 98 and 108) failed to bind in every 
experiment (Fig. 8 A). There also was no binding to a con- 
trol peptide corresponding to a CD2 cytoplasmic sequence 
that was not rich in prolines (data not shown). 
Because peptide 2 bound GST/p56 lck best, we determined 
the effect on binding of truncating this peptide. The following 
peptides were synthesized, immobilized on Sepharose, and 
assayed for their ability to bind GST/p561ck: HI<PLPPSHI(, 
PLPPSHI( and HI<PLPPS. Only HI (PLPPSHI(  bound 
GST/p56 lck (Fig. 8 B). This peptide differed from peptide 2 
by the deletion of  PG on the NH2 terminus. The removal 
of  the HI< from either the NH2 terminus or the COOH 
terminus resulted in loss of  binding (Fig. 8 /3), suggesting 
either that the flanking basic amino acids are required for 
binding of  this peptide to the SH3 domain of  p561ok or that 
the peptide length must exceed seven residues. Although 
our studies do not distinguish between these possibilities, 
the sequences of  the first and second proline-rich regions 
are quite similar, the major difference being that the second 
has basic amino acids at both flanks of  the prolines, whereas 
the first has basic residues at the carboxy terminus only. 
The absence of NH2-terminal basic residues may explain 
the decreased ability of  the peptide derived from the first 
proline-rich region (peptide 1) to bind GST/p56 lck. 
The First Two Proline-rich Regions in the Cytoplasmic Tail of 
CD2 Are Not Required for Coupling to Signaling Pathways. 
Previous studies examining the structural requirements for 
signal transduction by human CD2 indicated that the first 
two proline-rich regions in the cytoplasmic domain of  hu- 
man CD2 were required for signal transduction by CD2 
(21, 36, 37). Chang et al. (21) demonstrated that a trunca- 
tion mutant retaining 77 amino acids, but not one retaining 
43 amino acids, of  the cytoplasmic domain of  human CD2 
could couple to a rise in free intracellular calcium ([Ca>]i) 
and IL-2 production, suggesting that an essential sequence 
for human CD2 signal transduction lies between amino ac- 
ids 43 and 77. Point mutations on either side of  the second 
proline-rich domain did not affect IL-2 production, but a 
substitution of  DE for the HI< after the first proline-rich 
region abrogated signaling, consistent with a key role of  the 
first proline-rich region in CD2 signal transduction (37). 
This finding could not be corroborated by Hahn and 
Bierer (36), who found that the same HI (  to DE substitu- 
tion failed to have an effect on CD2 signaling. They did 
note that deletion of  either the first or second proline-rich 
region resulted in a reduction of  CD2-mediated IL-2 pro- 
duction, and elimination of  both regions completely abro- 
gated CD2 signaling (36). Therefore, although the studies 
differed on the relative importance of  the first and second 
proline-rich regions, both studies clearly defined this region 
as essential for CD2-mediated signaling. 
Our CY78 mutant, which retains the first two proline- 
rich regions in the cytoplasmic domain of  CD2, can bind 
p56 lck in vitro and, thus, is consistent with the notion that 
the binding of  p56 lck by CD2 is important in CD2-medi-  
ated signaling. On the other hand, based on the earlier 
functional studies, our CY49.69 would not be expected to 
couple to signaling pathways even though we find that it 
binds p56 lck in vitro (36, 37). Therefore, we investigated 
the possibility that CY49.69 could couple to signaling 
pathways in T cells. To this end, we expressed F.L. rat 
Figure 8. Binding of GST/ 
p56 kk by proline-rich peptides. 
(a) Proline-rich peptides in the 
cytoplasmic domain of CD2 can 
bind p56 lck. l l-mer peptides 
corresponding to five proline- 
rich regions (1-5) in the cyto- 
plasmic domain of CD2 were 
synthesized (peptide 4 is a 12- 
mer; a glycine was added to the 
NH2 terminus to prevent cy- 
clization of the NH2-terminal 
glutamine). The locations and sequences of the peptides are indicated in the diagram. The peptides were coupled to Sepharose and used to precipitate pu- 
dried GST/p56 lck. (b) The effect of truncations on the ability ofpeptide 2 tobind p56 lck. Peptides indicated above the lanes in Fig. 8 b were synthesized, 
conjugated toSepharose, incubated with equivalent concentrations of purified GST/p56 l'k, and immunoblotted with anti-GST antiserum. 
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Figure 9. Anti-CD2 mAb (OX-54 and 
OX-55) trigger an increase in [Ca2+]i in 
F.L. CD2 and CY49.69 when expressed in 
Jurkat. The calcium-sensitive fluorescence 
of a suspension of Jurkat cells expressing 
F.L. rat CD2 and CY49.69 was monitored 
over time. At the indicated times, the cells 
were stimulated with 5 Dg of OX-54 and 5 
b~g of OX-55 for every 106 cells. Values for 
[Ca2+]i (nM) were calculated as described 
and are indicated on the righthand side of 
the figure (31). These data re representative 
of at least hree separate experiments. 
CD2 and the CY49.69 mutant in the human T cell line, 
Jurkat, and assessed the ability of  each to couple to a rise in 
[Ca2+]i and to produce IL-2 after CD2 stimulation. 
As previously described, F.L. CD2 can stimulate a rise in 
[Ca2+]i when activated with a pair of  anti-rat CD2 mAb 
(OX-54 and OX-55; Fig. 9). Similarly, the CY49.69 con- 
struct stimulated a rise in [Ca2+]i comparable to that seen 
with F.L. CD2 when activated with OX-54 and OX-55 
(Fig. 9). To determine whether these constructs are capable 
of  producing IL-2 in response to anti-CD2 stimulation, we 
stimulated F.L. CD2 Jurkat and CY49.69 with PMA alone, 
the combination of  OX-54,  OX-55,  and PMA, or the 
combination of  C305 (anti-TCR.) and PMA. As previously 
demonstrated, stimulation of  F.L. rat CD2 results in IL-2 
production comparable to that seen after TCP,  stimulation 
(Table 1). CY49.69 also produced IL-2 in response to CD2 
stimulation, and the amount of  IL-2 produced was compa- 
rable to that elicited by TCR. stimulation (Table 1). These 
data demonstrate that the first two proline-rich regions in 
the cytoplasmic tail of  CD2 are not required for CD2 to 
transduce signals. 
D iscuss ion  
In this report we have examined the mechanism by 
which CD2 and p56 kk associate. The interaction between 
these does not require the coexpression of  other leukocyte- 
specific molecules, as evidenced by the ability of  CD2 and 
p56 kk to associate in COS cells and Sf9 cells. Therefore, al- 
though CD2 coprecipitates with a number of  lineage- 
restricted molecules, including the TCR., CD4, CD45, and 
CD53, none of  these need be present for CD2 to associate 
with p56 kk (11, t2). The association requires the cytoplas- 
mic domain of  CD2, to which the SH3 domain of  p56 lck 
binds. Truncation mutants of  CD2 reveal two regions 
whose deletion leads to a substantial decrease in the amount 
of  p56 lck that coprecipitates with CD2. When the cytoplas- 
mic domain is shortened from 105 to 85 amino acids, there 
is a 70% decrease in the amount of  p56 kk binding, relative 
to full length CD2. As the cytoplasmic tail of  CD2 is fur- 
ther shortened from 78 to 40 amino acids, virtually all 
binding to p56 lck is lost. Each of  these regions contains a 
proline-rich sequence that, in the form of  an immobilized, 
synthetic peptide, binds p56 kk. Thus proline-rich sequences, 
which are a distinctive feature of  the CD2 cytoplasmic do- 
main, allow this transmembrane receptor to couple to p56 lck 
by binding its SH3 domains. 
SH3 domains, which are found primarily in enzymes and 
other molecules involved in signal transduction, mediate 
protein-protein i teractions (38). A striking feature of  the 
known binding sites for SH3 domains is the frequency of  
proline residues (32). The sequence requirements for inter- 
actions with the SH3 domains of  most proteins, including 
p56 lck, are not known. Yu et al. (39) recently screened a
9-mer combinatorial peptide library in order to identify 
amino acid sequences that can bind the SH3 domain of  
p60 src. The library, which was in the form of  XXXPPX-  
PXX, was biased to include a common PPXP motif. Two 
classes ofpeptides bound to the Src SH3 domain. All mem- 
Table 1.  IL-2 Production (pg/ml) in Full-Length CD2 and CY49.69Jurkat Clones after Stimulation with Anti-Rat CD2 (0X-54 and 
0X-55) or Anti-TCR mAb (C305) 
Experiment 1 Experiment 2 
Clone PMA CD2 + PMA TC1K + PMA PMA CD2 + PMA TC1K + PMA 
Full-length < 10 392 641 < 10 > 1,500 1,570 
CY49.69 <10 835 707 <10 407 848 
106 cells were stimulated overnight with PMA (10 ng/ml) alone, anti-rat CD2 mAb (25 mg/ml of OX-54 and OX-55) plus PMA, or anti-TCR 
mAb (1:500 dilution from C305 ascites) plus PMA. Culture supernatants were assayed for IL-2 as described inMaterials and Methods. Data presented 
are representative of at least four independent experiments. At least wo separate clones for each construct were evaluated. 
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bers of the first group had an R_XL motif  at the amino ter- 
minus and a leucine at position 6; the majority had a basic 
amino acid, usually arginine, at the penultimate position 
and a hydrophobic amino acid at the carbox 3" terminus. 
Peptide 2 from the CD2 cytoplasmic domain also has an 
amino terminal RXL  motif  and an arginine at the equiva- 
lent of  the penultimate position of the library peptide. In 
the CD2 sequence this arginine (which is the COOH ter- 
minus of peptide 2) is followed by a hydrophobic residue. 
Peptide 4 contains the motif  PPLPR, which is the com- 
mon feature of the second class of Src SH3 domain-bind- 
ing peptides. Thus, both CD2 sequences that bind p56 kk 
share key features with peptides elected for their abili b- to 
bind to the SH3 domain of a closely related PTK, p60Srq In 
contrast, analysis of the other proline-rich sequences in 
CD2 fails to reveal similarities between these sequences and 
the Src SH3 domain-binding peptides. 
By interacting with the SH3 domain of p56 kk, CD2 may 
influence the enzymatic activity of this PTK. Phosphoryla- 
tion ofa COOH-ternf inal  tyrosine residue (tyrosine 505 in 
p56 l~k) down regulates the activity of Src-like PTKs (40). 
The phosphory, lated COOH-ternf inal  tyrosine likely binds 
to the SH2 domain of  the kinase, causing the PTK to fold 
back on itself and rendering the kinase inactive. It has been 
proposed that an interaction between the SH3 domain and 
a proline-rich region in the COOH terminus of p56 kk fur- 
ther stabilizes this "closed" conformation (41). Indeed, nm- 
tations in the SH3 domain of Src-like PTKs, which would 
prevent his interaction, increase kinase activity (40). When 
p56 Ick binds to CD2, its SH3 domain is occupied, prevent- 
ing it from interacting with the COOH-tem~inal proline- 
rich region of p56 I&. This may destabilize the inactive con- 
formation of p56 lck and favor an "open" or active form of 
the kinase. It is possible, therefore, that there is an impor- 
tant qualitative difference between CD2-associated p56 kk 
and the p56 lck associated with receptors, such as CD4 or 
CD8, that, by interacting with the unique region of p56 kk, 
should not affect the stability of  the inactive form of the 
enzyme (42, 43). 
Previous studies by several investigators have focused on 
the potential importance of  proline-rich sequences for sig- 
naling by human CD2 (21, 36, 37). Mutants with as few as 
the first 77 an-fino acids of the cytoplasnfic domain of hu- 
man CD2 were capable of coupling to a rise in [Ca2+]i and 
IL-2 production, whereas truncations to ~<43 amino acids 
failed to couple to signaling pathways, suggesting that the 
region between amino acids 43 and 77 was required for 
CD2 signal transduction (21). This region contains the first 
two proline-rich domains. Mutational analysis of  this re- 
gion has led to conflicting results. Chang et al. (37) found 
that substitution of the HR with DE af}er the first proline- 
rich region, but not the second, resulted in a loss of  signal- 
ing by CD2. Alternatively, when Hahn and Bierer (36) 
made the same mutation, they failed to detect a change in 
IL-2 production after CD2 stimulation. Internal deletion 
mutants excising either of  the PPPGHR, motifs in the first 
and second proline-rich regions reduced CD2-mediated 
IL-2 production, and deletion of this motif  in both regions 
176 CD2 Association with p56 kk 
resulted in complete abrogation of CD2-mediated IL-2 
production (36). Consistent with the findings presented 
above, an internal deletion lacking amino acids 19-77 of  the 
cytoplasmic tail of  human CD2 also failed to produce IL-2 
in response to CD2 stimulation (36). 
In our experiments, deletion of the first and second pro- 
line-rich regions (CY49.69) had little if any effect on the 
ability of  CD2 to couple to a rise in [Ca2+]i or to IL-2 pro- 
duction. Although the rat and human sequences differ 
slightly in the first two proline-rich regions, they are iden- 
tical in the fourth and fifth proline-rich regions (amino ac- 
ids 80-103 in the human), suggesting that a constrnct com- 
parable to our CY49.69 in the hmnan would signal. The 
reason for the discrepancy between our results and those of 
Hahn and Bierer (36) may lie in the way the constructs 
were made. One of Hahn and Bierer's constructs retained 
the sequences between the proline-rich domains and the 
other excised a larger portion of  the cytoplasmic domain 
than our CY49.69. This may have resulted in secondary- 
structural changes that prevented the fourth proline-rich 
region from binding p56 Ick. 
Our studies indicate that specific proline-rich regions in 
the COOH-ternf inal  half of  the cytoplasmic domain of  
CD2 mediate the direct interactions of  CD2 and p56 kk by 
binding the SH3 domain of  p56 lck. Carmo et al. (13), how- 
ever, have shown that p56 lck is present in CD2 immuno- 
precipitates from the CY40 mutant expressed in Jurkat. 
These immunoprecipitations were performed using Brij 96 
lysates. It is possible that the proximal 40 amino acids in the 
cytoplasmic domain of CD2 may associate with other mol- 
ecules that mediate an association with p56 lck and that these 
associations are not maintained in the conditions we used 
for our studies (1% NP-40 lysis buffer). Our studies indi- 
cate that the first 40 amino acids do not participate in the 
direct binding to p56 lck. Neither our CY40 truncation m- 
tant nor our T7-40 fusion protein coprecipitated with 
GST/p56 kk. Additionally, our 7.41 internal deletion mu- 
tant, which lacks anfino acids 7-4 l  of  the cytoplasnfic tail 
of  CD2, consistently bound p56 kk better than F.L. CD2. 
Because the CD2 sequences that bind the p56 kk SH3 
domain resemble the consensus equences for binding the 
p60 s~ SH3 domain, interactions between CD2 and the Src 
family may not be limited to p56 I~k but may involve other 
members as well. Several observations indicate that this is 
likely the case. Both p596'" and p56 kk coinmmnoprecipitate 
with CD2 fi'om T cells and NK cells, raising the possibility 
that p596" directly interacts with CD2 (13, 14, 27). We 
also have fbund that another Src-like kinase, p54bn coim- 
munoprecipates with CD2 when the latter is expressed in 
I~I3L, a rat basophilic leukemia line that does not express 
p56 I& (G. Bell; unpublished observations). We are cur- 
rently investigating whether the SH3 domains ofp596'" and 
p54 ly" mediate these interactions with CD2 and whether 
they bind the same CD2 sequences as p56 kk. 
Although our results are consistent with a role for p56 l& 
in CD2-mediated signaling, we cannot conclude that the 
association with p56 k'k is sufficient or even necessary- for 
CD2 signaling. An interesting possibility, not addressed in 
our study, is that signaling molecules other than the Src- 
like PTKs interact with CD2 using a mechanism similar to 
the one described here. Of  note in this regard, the peptide 
corresponding to the first proline-rich region (peptide 1) 
binds p56 l~k poorly and does not resemble the Src SH3 do- 
main-binding peptides. Nevertheless, deletion of  this re- 
gion in human CD2 results in a 10-fold reduction of  CD2-  
mediated IL-2 production (36). One possibility is that this 
proline-rich region binds to the SH3 domain of  signaling 
molecule, other than a Src-like PTK, which may be re- 
quired for CD2-mediated signal transduction. 
CD2-mediated signaling requires the presence of  the 
TCR or of  receptors that contain members of  the TCR 
chain family (16, 44). Perturbation of  CD2 on T cells leads 
to the tyrosine phosphorylation f the TCR.-/~ chain, and it 
is likely that this event is crucial for CD2 signaling (20, 26). 
Tyrosine phosphorylation triggers an association between 
TC1K-~ and ZAP70, a PTK thought to play a critical role 
in TC1K signaling (45). As noted above, CD2 appears to be 
in physical proximity with the TCR and, under certain 
conditions, TC1K-~ coimmunoprecipitates with CD2 (12). 
The demonstration that CD2 associates with p56 lck suggests 
that, like the CD4 and CD8 coreceptors, CD2 may bring 
p56 kk into proximity with potential substrates within the 
TC1K complex. Furthermore, the mechanism by which 
CD2 associates with p56 kk may make CD2 uniquely suited 
to stimulate the phosphorylation f TCR components. 
This work was supported by the Arthritis Foundation, United States Public Health Service grants K11- 
AI00999, 17,29-AI34911, RO 1-CA52669, RO 1-AI26644, and the Department of Veterans Affairs. 
Address correspondence to GregoD, M. Bell, Department of Medicine, Veterans Affairs Medical Center, 
The University of California, San Francisco, CA 94121. 
ReceivedJbr publication 16 May 1995 and in revised form 1 September 1995. 
References 
1. Tiefenthaler, G., T. Hunig, M.L. Dustin, T.A. Springer, and 
S.C. Meuer. 1987. Purified lymphocyte function-associated 
antigen-3 and TI 1 target structure are active in CD2-medi- 
ated T-cell stinmlation. Eur. J. Immunol. 17:1847-1850. 
2. Hahn, W.C., E. Menu, A.L.M. Bothwell, B.J. Sims, and B.E. 
Bierer. 1992. Overlapping but nonidentical binding sites on 
CD2 for CD58 and a second ligand CD59. Science (Wash. 
DC). 256:1805-1807. 
3. Kato, L., M. Koyanagi, H. Okada, T. Takanashi, Y.W. 
Wong, A.N. Barclay, A.F. Williams, K. Okamura, and H. 
Yagita. 1992. CD48 is a counter-receptor f mouse CD2 
and is involved in T cell activation.J. Exp. Med. 176:1241- 
1249. 
4. Meuer, S.C., I<.E. Hussey, M. Fabbi, M. Fox, O. Acuto, 
K.A. Fitzgerald, J.C. Hodgon, J.P. Protentis, S.F. Schloss- 
man, and E.L. P, einherz. 1984. An alternative pathway of 
T-cell activation: a functional role of the 50 kd sheep eryth- 
rocyte receptor protein. Cell. 36:897-906. 
5. Siliciano, R.F., J.C. Pratt, 1<.E. Schmidt, and E.L. Reinherz. 
1985. Activation of cytolytic T lymphocyte and natural killer 
cell function through the T11 sheep ewthrocyte binding pro- 
tein. Nature (Lond.). 317:428-430. 
6. Bierer, B., A. Peterson, J.C. Gorga, S.H. Hermlan, and SJ. 
Burakoff. 1988. Synergistic T cell activation via the physio- 
logical igands for CD2 and the T cell receptor. J. Exp. Med. 
168:1145-1156. 
7. Springer, T.A., M.L. Dustin, T.K. Kishinmto, and S.D. Mar- 
lin. 1987. The lymphocyte function-associated LFA-1, CD2, 
and LFA-3 molecules: cell adhesion receptors of the immune 
system. Annu. Rev. lmmunol. 5:233-252. 
8. Guckel, G., C. Berek, M. Lutz, P. Altevogt, V. Schirr- 
macher, and B.A. Kyewski. 1991. Anti-CD2 antibodies in- 
duce T cell unresponsiveness in vivo.J. Exp. ,lied. 174:957- 
177 Bell et al. 
967. 
9. Killeen, N., S.G. Stuart, and D.R.. Littman. 1992. Develop- 
ment and fuction of T cells in mice with a disrupted CD2 
gene. EMBO (Eur. Mol. Biol. Organ.) J. 11:4329--4336. 
10. Boussiotis, V.A., G.J. Freeman, J.D. Griffin, G.S. Gray, J.G. 
Gribben, and L.M. Nadler. 1994. CD2 is involved in main- 
tainance and reversal of human alloantigen-specific clonal an- 
ergy. J. Exp. Med. 180:1665-1673. 
II. Brown, M.H., D.A. Cantrell, G. Bratts, M.J. Crumpton, and 
M. Gulberg. 1989. The CD2 antigen associates with the T 
cell antigen receptor CD3 complex on the surface of human 
T lymphocytes. Nature (Lx, nd.). 339:551-553. 
12. Beyers, A.D., L.L. Spruyt, and A.F. Williams. 1992. Molecu- 
lar associations between the T-lymphocyte antigen receptor 
complex and the surface antigens CD2, CD4, or CD8 and 
CD5. Proc. Natl. Acad. Sci. USA. 89:2945-2949. 
13. Canno, A.M., D.W. Mason, and A.D. Beyers. 1993. Physical 
association of the cytoplasmic domain of CD2 with the ty- 
rosine kinases p56 kk and p596'". Eur. J. lmmunol. 23:2196- 
2201. 
14. Gassman, M., K.E. Amrein, N.A. Flint, B. Schraven, and P. 
Burn. 1994. identification of a signaling complex involving 
CD2, ~ chain and p59 t~'" in T lymphocytes. Eur. J. bnmunol. 
24:139-144. 
15. Bockenstedt, L., M.A. Goldsmith, M. Dustin, D. Olive, T.A. 
Springer, and A. Weiss. 1988. The CD2 ligand LFA-3 acti- 
vates T cells but depends on the expression and ~hnction of 
the antigen receptor.J, lmmunol. 141:1904-1911. 
16. Moingeon, P., J.L. Lucich, D.J. McConkey, F. Letourneur, 
B. Malissen, J. Kochan, H.S. Chang, H.R. Rodewald, and 
E.L. Reinherz. 1992. CD3~ dependence of the CD2 path- 
way of activation in T lymphocytes and natural killer cells. 
Proc. Nad. Acad. Sci. USA. 89:1492-1496. 
17. Alcover, A., M.J. Weiss, J.F. Daley, and E.L Reinherz. 1986. 
The T ll glycoprotein is functionally linked to a calcium 
channel in precursor and mature T-lineage cells. Proc. Natl. 
Acad. Sci. USA. 83:2614-2618_ 
18. June, C.A., J.A. Ledbetter, P.S. Rabinovitch. p.J. Martin, 
P.G, Beatty. and J.A. Hansen. 1986. Distinct patterns of 
transmembrane calcium flux and intracellular calcium mobili- 
zation after differentiation a tigen cluster 2 (E rosette recep- 
tor) or 3 (T3) stimulation of human lymphocytes.J. Clin. In- 
~,est. 77:1224-1232. 
19. Monostori, E., D. Desai, M.H. Brown, D.A. Cantrell, and 
M.J. Crumpton. 1989. Activation of human T lymphocytes 
via the CD2 antigen results in tyrosine phosphorylation fT 
cell antigen receptor ~-chains.ff. lmmztnol. 144:1010-1014. 
20. Samelson, L.E., M.C. Fletcher, J.A. Ledbetter, and C.A. 
June. 1990. Activation of tyrosine phosphowlation in human 
T cells via the CD2 pathway.J. Immunol. 145:2448-2454. 
21. Chang, H., P. Moingeon, P. Lopez, H. Krasnow, C. Steb- 
bins, and E l .  Reinherz. 1989. Dissection of the human CD2 
intracellular domain.J. Exp. Med. 169:2073-2083. 
22. He. Q., A.D. Beyers, A.N. Barclay, and A.F. Williams. 1988. 
A role in transmembrane signaling for the cytoplasmic do- 
main of the CD2 T lymphocyte surface antigen. Cell. 54: 
979-984. 
23. Seed, B.. and A. Aruffo. 1987. Molecular cloning of the CD2 
antigen, the T-cell erythrocyte r ceptor, by a rapid imnmn- 
oselection procedure. Proc. Natl. Acad. Sci. USA. 84:3365-3369. 
24. Sewell, W.A., M.H. Brown, J. Dunne, M.J, Owen, and M.J. 
Crumpton. 1986. Molecular cloning of the T-lymphocyte 
glycoprotein surface CD2 (T11) antigen. Proc. Natl. Acad. Sci. 
USA. 83:8718-8722. 
25. Koretzky, G.A, J. Picus, T. Schultz, and A. Weiss. 1991. Ty- 
rosine phosphatase CD45 is required for T-cell antigen re- 
ceptor and CD2-mediated activation of a protein tyrosine ki- 
nase and interleukin 2 production. Proc. Natl. Acad. Sci. U&d. 
88:2037-2041. 
26. Danielian, S., R. Fagard, A. Alcover, O. Acuto, and S. Fis- 
cher. 1991. The tyrosine kinase activity of p56 kk is increased 
in human T cells activated via CD2. Eur. J. Immunol. 21: 
1967-1970. 
27. Bell, G.M., J. Bolen, andJ.B. Imboden. 1992. Association of 
Src-like protein tyrosine kinases with the CD2 cell surface 
molecule in rat T lymphocytes and natural killer cells. Mol. 
Cell. Biol. 12:5548-5554. 
28. Spana, C., E. O'Rourke, J.B. Bolen, and J. Fargnoli. 1993. 
Analysis of the tyrosine protein kinase p561ck expressed as a 
glutathione-S-transferase fusion protein in Sf-9 cells. Protein 
E,vpressiotl a~zd Pur!fication. 4:390-397. 
29. Connack, B. 1991. Mutagenesis by the Polymerase Chain 
Reaction. hi Current Protocols in Molecular Biology. F.M. 
Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.G. 
Seidman, J.A. Smith, and K. StruM, editors. John Wile}" and 
Sons, Inc,, New York. 8.5.l-8.5.9. 
30. Selden, R.F. 1987. Current Protocols it] Molecular Biolog T. 
F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.G. 
Seidman, J.A. Smith, and K. Struhl, editors. John Wiley and 
Sons, Inc. New York. 9.2.1-9.2.6. 
31. Bell, G.M., W.E. Seaman, E.C. Nienfi, and J.B. Imboden. 
1992. The OX-44 molecule couples to signaling pathways 
and is associated with CD2 on rat T lymphocytes and a natu- 
ral killer cell line.J. Exp. :l,led. 175:527-536. 
32. Ren, R., B.J. Mayer, P. Cicchetti, and D. Baltimore. 1993. 
Identification of a ten-amino acid proline-rich SH3 binding 
site. Science (Wash. DC). 259:1157-1161. 
33. Li, N., A. Batzer, R. Daly, V. Yajnik, E. Skohfick, P. Char- 
din, D. Bar-Sa D, B. Margolis, andJ. Schlesinger. 1993. Gua- 
nine-nucleotide-releasing factor hSosl binds to Grb2 and 
links receptor tyrosine kinases to Ras signalling. Nature 
(Loud.). 363:85-88. 
34. Rozakis-Adcock, M., F. Ross, J. Wade, T. Pawson, and D. 
Bowtell. 1993. The SH2 and SH3 domains of mammalian 
Grb2 couple the EGF receptor to the Ras activator mSosl. 
Nature (Loud.). 363:83-85. 
35. Egan, S.E., B.W. Giddings, M.W. Brooks, L. Buday, A.M. 
Sizeland, and R.A. Weinberg. 1993. Association of Sos Ras 
exchange protein with Grb2 is implicated in 9"rosine kinase 
signal transduction and transformation. Nature (Lx}nd.). 363: 
45-51. 
36. Hahn, W.C., and B.E. Bierer. 1993. Separable portions of the 
CD2 cytoplasmic domain involved in signaling and ligand 
avidit T regulation. J. Exp. Med. 178: 1831-1836. 
37. Chang, H., P. Moingeon, R. Pedersen, J. Lucich, C. Steb- 
bins, and E.L. Reinherz. 199{3. Involvement ofthe PPPGHR 
motif in T cell activation via CD2. 1. Exp. Med. 172:351- 
355. 
38. Pawson, T., and G.D. Gish. 1992. SH2 and SH3 domains: 
from structure to function. Cell. 71:359-362. 
39. Yu, H., J.K. Chen, S. Feng, D.C. Dalgarno, A.W. Brauer, 
and S.L. Schreiber. 1994. Structural basis for the binding of 
proline-rich peptides to SH3 domains. Cell. 76:933-945. 
40. Superti-Furga, G., S. Fumagalli, M. Koegl, S.A. Courtneidge, 
and G. Draetta. 1993. Csk inhibition of c-Src activity re- 
quires both the SH2 attd SH3 domains of Src. EMBO (E,er. 
aIoI. Biol. Ot~r 12:2625-2634. 
41. Eck, M.J., S.K. Atwell, S.E. Shoelson, and S.C. Harrison. 
1994. Structure of the regulato W domains of the Src-family 
t2/rosine kinase Lck. Nature (ixmd.). 368:764-769. 
42, Turner, J.M., M.H. Brodsky, B.A. Irving, S.D. Levin, R.M. 
Perhnutter, and D.R. Littman. 199{I. Interaction of die 
unique N-ternfinal region ofty, rosine kinase p56 kk with cyto- 
plasmic domains of CD4 and CD8 is mediated by cysteine 
motifs. Cell. 60:755-765. 
43. Shaw, A,S., J. Chalupny, J.A. Whitney, C. Hammond, K.E. 
Amrein, P. Kavathas, B.M. Sefton, and J.K. Rose. 1990. 
Short related sequences in the cytoplasmic domains of C1)4 
and CD8 mediated binding to the amino-terminal domain of 
the p561ck vv,'rosine protein kinase. Mol. Cell. Biol. 10:1853- 
186(s 
44. Arulanandam, A.R.N., S. Koyasu, and E.k. Reinherz. 1991. 
T cell receptor-independent CD2 signal transduction i  
FcR + cells._]. Exp. Med. 173:859-868. 
45. Chan, A., B. Irving, J.D. Fraser, and A. Weiss. 1991. The 
TCR ~ chain associates with a tyrosine kinase and upon 
TCR stimulation associates with ZAP-70, a 70K Mr tyrosine 
phosphoprotein. Pro& ,\ratl. Acad. &i. USA. 88:9166-9170. 
178 CD2 Association with p56 kk 
